# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunct...
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and lowers the price targ...
HC Wainwright & Co. analyst Andrew Fein reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price...
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of ...
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-surge-over-400-says-oppenheimer/
HC Wainwright & Co. analyst Andrew Fein reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price...
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate o...